Designing the next generation of gene therapy treatments

GFP expression in the retinal vasculature The Ocular Gene Therapy Laboratory (OGTL) founded by Daniel M. Lipinski, DPhil, is dedicated to the development of novel therapies to prevent human blindness. Occupying >1,000 sq.ft. of research space within the Medical College of Wisconsin Eye Institute, OGTL provides the expertise and infrastructure to design the next generation of gene therapy treatments aimed at preventing retinal cell death or dysfunction.
OGTL News
Erika Shaw
February 06, 2019

Welcome – Erika Shaw joins the OGTL as a graduate student

Erika Shaw, a first year graduate student in the Neuroscience Doctoral Program (NDP), has elected to join the Lipinski Laboratory full time to complete her graduate studies.
+Read More

 
American Journal of Pathology
February 01, 2019

Publication – OGTL collaborative research is featured on the American Journal of Pathology (AJP) front cover

In collaboration with Dr Jeffery A. Medin, study leader and MACC Fund Professor, researchers from the OGTL, AOIP and Kassem Laboratory at the MCW Eye Institute, helped characterize the effects of acid ceramidase deficiency on ocular anatomy and function in a mouse model of Farber’s disease, a hyper-rare lysosomal storage disorder of which there has been fewer than 200 reported cases.
+Read More

 
Ramesh Periasamy, PhD
January 11, 2019

Welcome – Ramesh Periasamy joins OGTL as a post-doctoral fellow

Dr Ramesh Periasamy obtained his doctoral degree (PhD) in biomedical sciences from the University of Bern, Switzerland, and joins the OGTL from the laboratory of Dr Hamant Kanna, University of Massachusetts.
+Read More

 
 
Key Publications

Reid CA, Nettesheim, E.R., Connor, T.B., Lipinski DM.  Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD   Sci Rep   8(1):11763 (2018).

 
 
 

Reid CA, Ertel KJ, Lipinski DM.   Improvement of Photoreceptor Targeting via Intravitreal Delivery in Mouse and Human Retina Using Combinatory rAAV2 Capsid Mutant Vectors.   Invest Ophthalmol Vis Sci.   2017 12 01;58(14):6429-6439.

 
 
 

Lipinski DM, Barnard AR, Singh MS, Martin C, Lee EJ, Davies WIL, MacLaren RE.   CNTF Gene Therapy Confers Lifelong Neuroprotection in a Mouse Model of Human Retinitis Pigmentosa.   Mol Ther.   2015 Aug;23(8):1308-1319.

 
 
 

Singh MS, Charbel Issa P, Butler R, Martin C, Lipinski DM, Sekaran S, Barnard AR, MacLaren RE.   Reversal of end-stage retinal degeneration and restoration of visual function by photoreceptor transplantation.   Proc Natl Acad Sci U S A.   2013 Jan 15;110(3):1101-6.

 

Histology - retinal layers

Upcoming Events
March 6, 2019 Timothy Wells, MD, MS
“Ptosis, Compensatory Frontalis Spasm, and Dry Eye: A Common Clinical Triad”
Ophthalmology Grand Rounds
Ophthalmology and Visual Sciences
Medical College of Wisconsin
March 25, 2019 Neena Haider, PhD
“Gene identification to gene therapy: development of the first broad spectrum therapy for inherited retinal disease”
Vision Science Distinguished Lecture Series
Ophthalmology and Visual Sciences
Medical College of Wisconsin
Milwaukee, WI, USA
April 28 - May 02, 2019 The Association for Research in Vision and Ophthalmology - ARVO
Annual Meeting
Vancouver, Canada

Medical College of Wisconsin Eye Institute
925 North 87th Street
Milwaukee, WI 53226
414-955-2062
Fax: 414-955-6690

Email OGT
© 2019 Medical College of Wisconsin
top